BMS’ Opdivo evens the score in melanoma with two new FDA green lights

Tracy Staton

Thanks to an FDA decision over the weekend, Bristol-Myers Squibb's immunotherapy has caught back up to Merck's Keytruda in . And it won a new combination approval from the FDA to boot.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS